“I think partners generally see neuropathic pain as a huge area of unmet need and a huge area of opportunity. And so, there will be a number and are a number of interested partners to have these discussions with.” – Lexicon’s CEO Mike Exton on how the company will seek a partner to augment its clinical development capabilities and provide commercial reach. Find out more: Lexicon’s Sunny Take Does Not Sway Investors About Phase IIb DPNP Miss
“We would appreciate it if Japan will open up support for foreign startups for their R&D presence in the country. If Japan offers some benefit to those foreign startups which lead their projects in the country, that could encourage growth of the scene [of entire biopharma startups].” – iPark’s CEO Toshio Fujimoto on the need to activate the biopharma sectors in Japan and develop the country’s R&D and business appeal for future startups. Find out more: Japan-Korea Venture Collab Grows With VC And Regulatory Meetups
“We would like most of the manufacturing to be centric in locations where it is most economical. This may not be the case going forward looking at every country’s ambition to be self-sufficient and ambition to be balanced from a tariff perspective or anything else.” – Cipla’s CEO Umang Vohra on how government policies will shape the evolution of manufacturing networks. Find out more: India Pharma Chiefs On Future Manufacturing Networks And Specter Of Tariffs
“I think it is better for us to play in a market in which we compete for products which are not aggressively competed by big pharma. So, we have a relatively small subset because we are a small company, and we need to recognize and reflect that in our action and plan.” – Sun Pharmaceutical Industries’ Dilip Shanghvi on the company’s business strategies to develop its growing ambition. Find out more: Sun Sets Up For PD-L1 Play With Checkpoint Acquisition
“We really think that each individual is going to present differently, so somebody will have cognitive decline and inflammation, some will have cognitive decline and metabolic disorders. It’s our thought that this is going to end up with combination therapy and precision medicine, much like cancer is treated today.” – Alzheimer’s Drug Discovery Foundation’s Karen Harris on the company’s investment outlook and the future of targeted treatment. Find out more: ADDF’s Harris On Alzheimer’s Outlook And Investment
“I’m a big believer in neuroscience. I think there are amazing things that still need to be done on the neurodegeneration side and in psychiatry side. The brain as a black box is getting slightly less dark, imaging has been a great help and there are new molecules, even those that are not perfect, that actually are pushing the boundaries of science. That’s clearly an area where we will continue investing.” – Sofinnova Partners’ Antoine Papiernik on how the industry’s interest is shifting, and which areas most likely to attract investment. Find out more: What’s Hot And What’s Not For Sofinnova
“We believe that we could launch in multiple markets … we have the learning of doing this business in many developing markets, which will help us build out our foray into the medical devices area. If you look at patient centricity, then one has to look at not only medicines, but companion diagnostics, imaging, med tech devices and I think all of these play a very critical role in terms of solving for patient problems or diseases.”– Zydus Lifesciences’ Sharvil Patel on the company’s future plans and how they align with the Indian major’s global ambitions in medtech. Find out more: Zydus’s Amplitude Acquisition Marks Global Medtech Entry With High Potential In India
“You need to power a digital mindset in your company. This is not only a great technologist, but it’s helping business partners understand the role technology can play in transforming industry and compressing time for patients.” – MSD’s Dave Williams on the need to leverage technology and bring in innovators with a growth mindset. Find out more: MSD’s CIDO Williams: ‘We Must Shorten Technology Adoption Cycles’
“You comb through an incredible amount of data trying to find that needle in the haystack, which is a patient who may not have been diagnosed yet, or may have been diagnosed, but still has significant levels of proteinuria, and that’s how we do it.” – Novartis’ Victor Bultó on the company’s plans to use digital technology like AI to comb through data and target potential candidates. Find out more: With Fabhalta’s C3G Approval, Now Novartis Has To Find The Patients
“The difference is that HIV docs forever have been used to only oral options, and so they used to write the script, either handing it to the patient or putting it in the electronic medical record, and then they’re done – the patient picks it up, and it goes off from there. So adjusting those providers to actually administering drugs in their clinic has taken some time for that implementation to ramp up.” ViiV Healthcare’s Kimberly Smith on treatment options for HIV and acknowledging the complexity of new drugs. Find out more: Gilead Pushes PrEP Envelope As ViiV Explores Self-Administered, Long-Acting Drugs
